On May 8th, Dr. David Buechner, renowned expert in mild traumatic brain injury (mTBI), delivered a captivating talk to a room packed with trial attorneys and doctors. Dr. Buechner, associated with Paragon Medical Group, presented an array of cutting-edge diagnostic tools aimed at providing objective diagnoses for mTBI. Alongside him was Alejandro Blanco, a prominent trial attorney and organizer of Connectionology, who engaged in a simulated scenario to assess the validity of these diagnostic methods. The talk also delved into the treatment options available for mTBI patients, highlighting a novel therapy called Acellular Nanoparticle (ANP) Therapy. This blog post explores the key takeaways from Dr. Buechner’s talk and sheds light on the groundbreaking approach of Paragon Medical Group.
Diagnostic Tools for mTBI:
Dr. Buechner commenced the talk by introducing a comprehensive range of diagnostic tools utilized at Paragon Medical Group. These tools, including Diffusion Tensor Imaging (DTI), oculomotor dysfunction testing, evoked EEG, IMPACT Testing, and a proprietary blood test, enable an objective diagnosis of mTBI. Of particular significance is the proprietary blood test developed by Paragon Medical Group. This groundbreaking test detects mTBI with remarkable sensitivity, even several months after the injury. It accomplishes this by measuring the concentration of two acute biomarkers in the blood, one indicative of neuronal cell death and the other of glial cell death.
Treatment Options and Progress Benchmarking:
Acknowledging the need for long-term medical care in mTBI cases, Dr. Buechner recommended a life care plan to the audience. He then introduced the audience to Acellular Nanoparticle (ANP) Therapy, a groundbreaking treatment for mTBI. Dr. Buechner shared multiple case studies demonstrating significant clinical and functional improvements resulting from three sessions of ANP nebulization. The therapy exhibited its efficacy through the restoration of normal white matter tracts post-therapy, which were initially abnormal. DTI, a preferred benchmarking method for progress assessment, effectively highlighted white matter tract dysfunction even in cases where traditional MRI scans did not reveal abnormalities.
Proprietary Methods and Patient-Focused Approach:
The diagnostic, treatment, and progress benchmarking methods discussed by Dr. Buechner are proprietary and perfectly aligned with Paragon Medical Group’s data-driven and patient-focused mission. The overarching goal of the group is to prioritize the patient’s well-being above all else, with the aim of returning them to a pain-free and normal life following a motor vehicle accident. Dr. Buechner’s talk merely scratched the surface of the myriad ways Paragon Medical Group consistently exceeds this objective on a daily basis.
Dr. David Buechner’s recent talk on mild traumatic brain injury (mTBI) showcased the remarkable advancements in diagnostic tools, treatment options, and progress benchmarking. Paragon Medical Group’s proprietary blood test, along with a range of other diagnostic methods, enables objective diagnoses of mTBI with exceptional sensitivity. The introduction of Acellular Nanoparticle (ANP) Therapy demonstrated promising results, with significant clinical and functional improvements observed in patients. With a strong commitment to data-driven approaches and a patient-focused mindset, Paragon Medical Group remains at the forefront of providing comprehensive and effective care to those affected by mTBI.
